AANEM News Express

AANEM News Express

Science News: Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis

11/4/2021
 
Submitted by: Niranjan Singh

Guilhem Solé, Stéphane Mathis, Diane Friedman, Emmanuelle Salort-Campana, Céline Tard, Françoise Bouhour, Armelle Magot, Djillali Annane, Bernard Clair, Gwendal Le Masson, Antoine Soulages, Fanny Duval, Louis Carla, Marie-Hélène Violleau, Tiphaine Saulnier, Sandrine Segovia-Kueny, Léa Kern, Jean-Christophe Antoine, Guillemette Beaudonnet, Frédérique Audic, Laurent Kremer, Jean-Baptiste Chanson, Aleksandra Nadaj-Pakleza, Tanya Stojkovic, Pascal Cintas, Marco Spinazzi, Alexandra Foubert-Samier, Attarian. Neurology 2021, 96:e2109-e2120

Summary: Among 3,558 patients with MG registered in the French database for rare disorders, 34 (0.96%) had COVID-19. The mean age at COVID-19 onset was 55.0 ± 19.9 years (mean MG duration: 8.5 ± 8.5 years). By the end of the study period, 28 patients recovered from COVID-19, 1 remained affected, and 5 died. Only high Myasthenia Gravis Foundation of America (MGFA) class (≥IV) before COVID-19 was associated with severe COVID-19 (p = 0.004); factors that were not associated included sex, MG duration, and medium MGFA classes (≤IIIb). The type of MG treatment had no independent effect on COVID-19 severity.

This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes.

Comments: This is a retrospective analysis of impact of coronavirus disease 2019 in a French cohort of myasthenia gravis.  The study did not find evidence that use of immunosuppressant and corticosteroid has adverse outcome.


View Related News Stories:

  EducationScience NewsNSEB


Recent AANEM News

Remembering George Kraft, MD, MS

The American Clinical Neurophysiology Society to Hold Another Townhall Meeting of Clinical Neurophysiology, Epilepsy, and Neuromuscular Fellowship Program Directors

Science News: Amyotrophic Lateral Sclerosis and Noninvasive Positive Pressure Ventilatory Support: "Nasal Noninvasive Ventilation" or "Noninvasive Ventilatory Support"?

CMS Finalizes Updates to Physician Fee Schedule

Advocacy in Action: State Liaison Leads the Way for Patient Advocacy in Washington and Beyond





Advertisement

ABEM

Advertisement

Donate

Advertisement